Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy

Bioconjugate Chemistry

Volumn 21, Issue 8, 2010, Pages 1513-1519

  Kim, Insoo ^f   Kim, Tae Hyung ^b   Ma, Kyungwan ^a   Lee, Eun Seong ^c   Kim, Dongin ^d   Oh, Kyung Taek ^e   Lee, Don Haeng ^f   Lee, Kang Choon ^b   Youn, Yu Seok ^a  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e Chung Ang University   (South Korea)

^f Inha University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; BODY FLUIDS; PARTICLE SIZE; POLYETHYLENES; PROTEINS;

2-IMINOTHIOLANE; ANTIDIABETIC; HETEROBIFUNCTIONAL POLYETHYLENE GLYCOLS; HUMAN SERUM ALBUMINS; HYPOGLYCEMIC EFFICACY; IN-VIVO; LIFESPANS; MALEIMIDES; MONOMER FRACTIONS; SULFHYDRYL GROUPS;

POLYETHYLENE GLYCOLS;

2 IMINOTHIOLANE; EXENDIN 4; HUMAN SERUM ALBUMIN; HUMAN SERUM ALBUMIN EXENDIN 4; HUMAN SERUM ALBUMIN EXENDIN 4 MACROGOL; MACROGOL; MALEIMIDE; N HYDROXYSUCCINIMIDE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING SITE; DRUG CONJUGATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; HYPOGLYCEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

MUS;

EID: 77955830619     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100143c     Document Type: Article

References (30)

1. Caliceti, P. and Veronese, F. M. (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 55, 1261-1277
2. Yoram, S., Marina, M., Sara, R., Ayala, S., Haim, T., and Mati, F. (2005) Albumin-insulin conjugate releasing insulin slowly under physiological conditions: A new concept for long-acting insulin Bioconjugate Chem. 16, 913-920
3. Goodman, L. and Gilman, A. G. (1995) The Pharmacological Basis of Therapeutics, McGraw-Hill, New York.
4. Deacon, C. F. (2004) Therapeutic strategies based on glucagon-like peptide 1 Diabetes. 53, 2181-2189
5. David, P., Carolyn, J., Pam, S., Sonali, N., Liz, R., Ron, G., Kim, C., and Andrew, Y. (2001) Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1 Drug Dev. Res. 53, 260-267
6. Davidson, M. B., Bate, G., and Kirkpatrick, P. (2005) Exenatide Nat. Rev. Drug Discovery 4, 713-714
7. Xu, G., Stoffers, D. A., Habener, J. F., and Bonner-Weir, S. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats Diabetes 48, 2270-2276
8. Szayna, M., Doyle, M. E., Betkey, J. A., Holloway, H. W., Spencer, R. G., Greig, N. H., and Egan, J. M. (2000) Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats Endocrinology 141, 1936-1941
9. Edwards, C. M., Stanley, S. A., Davis, R., Brynes, A. E., Frost, G. S., Seal, L. J., Ghatei, M. A., and Bloom, S. R. (2005) Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers Am. J. Physiol. 281, 155-161
10. Chuang, V. T., Kragh-Hansen, U., and Otagiri, M. (2002) Pharmaceutical strategies utilizing recombinant human serum albumin Pharm. Res. 19, 569-577
11. Kratz, F. (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles J. Controlled Release 132, 171-183
12. Kim, J.-G., Baggio, L. L., Bridon, D. P., Castaigne, J.-P., Robitaille, M. F., Jette, L., Benquet, C., and Druker, D. J. (2003) Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo Diabetes 52, 751-759
13. Thibaudeau, K., Léger, R., Huang, X., Robitaille, M., Quraishi, O., Soucy, C., Bousquet-Gagnon, N., van Wyk, P., Paradis, V., Castaigne, J.-P., and Bridon, D. (2005) Synthesis and evaluation of insulin-human serum albumin conjugates Bioconjugate Chem. 16, 1000-1008
14. Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agerso, H., Veldhuis, J., Porksen, N., and Schmitz, O. (2002) Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes Diabetes 51, 424-429
15. Kurtzhals, P., Havelund, S., Jonassen, I., and Markussen, J. (1997) Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue J. Pharm. Sci. 86, 1365-1368
16. Markussen, J., Havelund, S., Kurtzhals, P., Andersen, A. S., Halstrom, J., Hasselager, E., Larsen, U. D., Ribel, U., Schäffer, L., Vad, K., and Jonassen, I. (1996) Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs Diabetologia 39, 281-288
17. Baggio, L. L., Huang, Q., Brown, T. J., and Drucker, D. J. (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53, 2492-2500
18. Subramanian, G. M., Fiscella, M., Lamousé-Smith, A., Zeuzem, S., and McHutchison, J. G. (2007) Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25, 1411-1419
19. Temming, K., Meyer, D. L., Zabinski, R., Dijkers, E. C., Poelstra, K., Molema, G., and Kok, R. J. (2006) Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels Bioconjugate Chem. 17, 1385-1394
20. Shin, B. S., Kim, C. H., Lee, M. N., Hur, M. W., Lee, K. C., Youn, Y. S., and Yoo, S. D. (2006) Pharmacokinetics of 125I-GST-TatdMt, a recombinant fusion protein possessing potent anti-obesity activity, after intravenous, nasal, oral, and subcutaneous administration Regul. Pept. 140, 74-80
21. Chae, S. Y., Jin, C. H., Shin, J. H., Son, S., Kim, T. H., Lee, S., Youn, Y. S., Byun, Y., Lee, M. S., and Lee, K. C. (2010) Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs J. Controlled Release 142, 206-213
22. Jin, C. H., Chae, S. Y., Son, S., Kim, T. H., Um, K. A., Youn, Y. S., Lee, S., and Lee, K. C. (2009) A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice J. Controlled Release 133, 172-177
23. Youn, Y. S., Na, D. H., Yoo, S. D., Song, S. C., and Lee, K. C. (2005) Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential Int. J. Biochem. Cell Biol. 37, 1525-1533
24. Chae, S. Y., Chun, Y. G., Lee, S., Jin, C. H., Lee, E. S., Lee, K. C., and Youn, Y. S. (2009) Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers J. Pharm. Sci. 98, 1556-1567
25. Lee, S. H., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., and Lee, K. C. (2005) Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1 Bioconjugate Chem. 6, 377-382
26. Lee, K. C., Chae, S. Y., Kim, T. H., Lee, S., Lee, E. S., and Youn, Y. S. (2009) Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent Regul. Pept. 152, 101-107
27. Youn, Y. S., Jung, J. Y., Oh, S. H., Yoo, S. D., and Lee, K. C. (2006) Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy J. Controlled Release 114, 334-342
28. Youn, Y. S., Chae, S. Y., Lee, S., Jeon, J. E., Shin, H. G., and Lee, K. C. (2007) Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability Biochem. Pharmacol. 73, 84-93
29. Baggio, L. L., Huang, Q., Cao, X., and Drucker, D. J. (2008) An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis Gastroenterology 134, 1137-1147
30. Shechter, Y., Mironchik, M., Rubinraut, S., Saul, A., Tsubery, H., and Fridkin, M. (2005) Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin Bioconjugate Chem. 16, 913-920